Literature DB >> 15376303

Reliability of histopathologic assessment for the differentiation of recurrent hepatitis C from acute rejection after liver transplantation.

Arie Regev1, Enrique Molina, Rosana Moura, Pablo A Bejarano, Amr Khaled, Phillip Ruiz, Kris Arheart, Mariana Berho, Cinthia B Drachenberg, Patricia Mendez, Christopher O'Brien, Lennox Jeffers, Andreas Tzakis, Eugene R Schiff.   

Abstract

Histopathologic assessment is considered essential for the differentiation of recurrent hepatitis C (RHC) from acute cellular rejection (ACR) after liver transplantation (LT); however, there is limited information regarding its reliability. The aim of this study was to determine the interobserver and intraobserver agreement of the histopathologic diagnosis of RHC vs. ACR, and to determine the reliability of specific histopathologic features for the differentiation of RHC from ACR. Liver biopsy specimens from 105 consecutive patients transplanted for hepatitis C virus (HCV)-related liver disease were studied retrospectively. All the biopsies were performed for evaluation of abnormal liver enzymes within the 1st year after LT. The slides were blindly coded and assessed by 5 liver-transplant pathologists, practicing at 3 medical centers. The pathologists were asked to render a diagnosis, and determine the severity of the disease. Four of the pathologists were asked to determine the presence and severity of 36 histopathologic features. A total of 34 of the samples were then blindly resubmitted to each of the 4 pathologists to determine the intraobserver agreement. There was a slight agreement (kappa = .12) among the 5 pathologists on the histopathologic diagnosis. All 5 pathologists were in agreement on the diagnosis of RHC in only 5 patients (5%) and on the diagnosis of ACR in only 2 patients (2%). The best agreement among any 4 pathologists was fair (kappa = .20). Slight to moderate agreement occurred on the main histological features considered to be important in the diagnosis of ACR. Intraobserver agreement ranged from slight (kappa = .19) to moderate (kappa = .42) among 4 pathologists. In conclusion, the histopathologic differentiation of RHC from ACR after LT had relatively low interobserver and intraobserver agreement rates, and hence showed low reliability. Histopathologic assessment should be used cautiously for the differentiation of RHC from ACR post-LT.

Entities:  

Mesh:

Year:  2004        PMID: 15376303     DOI: 10.1002/lt.20245

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  15 in total

1.  Molecular pathways differentiate hepatitis C virus (HCV) recurrence from acute cellular rejection in HCV liver recipients.

Authors:  Ricardo Gehrau; Daniel Maluf; Kellie Archer; Richard Stravitz; Jihee Suh; Ngoc Le; Valeria Mas
Journal:  Mol Med       Date:  2011-04-20       Impact factor: 6.354

2.  High frequency of central memory regulatory T cells allows detection of liver recipients at risk of early acute rejection within the first month after transplantation.

Authors:  Francisco Boix-Giner; Olga Millan; David San Segundo; Pedro Muñoz-Cacho; Esther Mancebo; Santiago Llorente; Lourdes Rafael-Valdivia; Antoni Rimola; Emilio Fábrega; Anna Mrowiec; Luis Allende; Alfredo Minguela; Jose M Bolarín; Estela Paz-Artal; Marcos López-Hoyos; Mercé Brunet; Manuel Muro
Journal:  Int Immunol       Date:  2015-08-12       Impact factor: 4.823

Review 3.  Histopathological evaluation of recurrent hepatitis C after liver transplantation: a review.

Authors:  Francesco Vasuri; Deborah Malvi; Elisa Gruppioni; Walter F Grigioni; Antonia D'Errico-Grigioni
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

4.  Immunological dysfunction during or after antiviral therapy for recurrent hepatitis C reduces graft survival.

Authors:  Pratima Sharma; Amy Hosmer; Henry Appelman; Barbara McKenna; Mohammad S Jafri; Patricia Sullivan; Robert J Fontana; Anna S Lok
Journal:  Hepatol Int       Date:  2013-10       Impact factor: 6.047

5.  New and Evolving Management Paradigms for Hepatitis C after Liver Transplantation.

Authors:  A Sidney Barritt; Jama M Darling; Paul H Hayashi
Journal:  Curr Hepat Rep       Date:  2011-09

6.  Noninvasive diagnosis of acute cellular rejection in liver transplant recipients: a proteomic signature validated by enzyme-linked immunosorbent assay.

Authors:  Omar Massoud; Julie Heimbach; Kimberly Viker; Anuradha Krishnan; John Poterucha; William Sanchez; Kymberly Watt; Russell Wiesner; Michael Charlton
Journal:  Liver Transpl       Date:  2011-06       Impact factor: 5.799

7.  Quantification of C4d deposition and hepatitis C virus RNA in tissue in cases of graft rejection and hepatitis C recurrence after liver transplantation.

Authors:  Alice Tung Wan Song; Evandro Sobroza de Mello; Venâncio Avancini Ferreira Alves; Norma de Paula Cavalheiro; Carlos Eduardo Melo; Patricia Rodrigues Bonazzi; Fatima Mitiko Tengan; Maristela Pinheiro Freire; Antonio Alci Barone; Luiz Augusto Carneiro D'Albuquerque; Edson Abdala
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-02-13       Impact factor: 2.743

8.  Design and validation of the biliary atresia research consortium histologic assessment system for cholestasis in infancy.

Authors:  Pierre Russo; John C Magee; John Boitnott; Kevin E Bove; Trivellore Raghunathan; Milton Finegold; Joel Haas; Ronald Jaffe; Grace E Kim; Margret Magid; Hector Melin-Aldana; Frances White; Peter F Whitington; Ronald J Sokol
Journal:  Clin Gastroenterol Hepatol       Date:  2011-01-14       Impact factor: 11.382

Review 9.  Natural history, treatment and prevention of hepatitis C recurrence after liver transplantation: past, present and future.

Authors:  Jérôme Dumortier; Olivier Boillot; Jean-Yves Scoazec
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

Review 10.  Post-liver transplant hepatitis C virus recurrence: an unresolved thorny problem.

Authors:  Alberto Grassi; Giorgio Ballardini
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.